Tilray Inc. (TLRY), a constituent in the munKNEE Pure-Play LP Pot Stock Index, quietly presented its final financial results today as a separate entity before merging with Aphria for the period ended March 31, 2021. The highlights are as follows:

Q4 Financial Highlights

(All results are presented in USD and compared to the previous quarter.

• Total Net Revenue: decreased 15% to $48M
  • Dried Cannabis: 44% of total net revenue
  • Cannabis Extract: 21%
  • Hemp: 35%
    • Canada: 57% of total net revenue
    • U.S.: 23%
    • Other: 20%
• Cannabis Revenue: decreased 24% to 65.4% of total revenue from 73%
  • Adult-Use: -23.3% to 62% of total cannabis revenue
  • Canadian Medical: -23.5% to 10% of total cannabis revenue
  • Int'l Medical: -26.3% to 27.5% of total cannabis revenue
  • Bulk: +0.5% from 0% in the previous quarter
• Hemp Revenue: increased 8.5% to 34.6% of total revenue from 27.1%
• Gross Profit: $13.5M
• Gross Margin: increased to 32% from 29%
  • Cannabis: increased to 35% from 33%
  • Hemp: decreased to 27% from 34%
• Net Profit (Loss): loss increased to $(340,955)M from $(3.0)M
• Net Profit (Loss)/Share: loss increased to $(2.01) from $(0.02)
• Adj. EBITDA: declined to $(6.3)M from $2.2M
• Cash on hand: increased 119% to $416.4M

Operational Highlights

• Cannabis:
  • Average Cost/g Sold: declined 4% to $3.56
  • Average net selling price/g: declined 16% to $5.00
• Hemp:
  • Average gross selling price/unit: $6.82

If you found the above analysis of interest check out the other recent quarterly reports from Hexo, Columbia Care, Ayr Wellness, Aurora, Canopy, Green Thumb, TerrAscend, Trulieve, Rubicon, Harvest Health, Valens, Cronos, Curaleaf, and Organigram.